Akoya Biosciences Inc (AKYA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Akoya Biosciences Inc (AKYA) has a cash flow conversion efficiency ratio of 1.225x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.21 Million) by net assets ($-5.89 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See AKYA net asset quality score to measure how much of total assets are equity-financed.
Akoya Biosciences Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Akoya Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Akoya Biosciences Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
Akoya Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Akoya Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
RBZ Jewellers Limited
NSE:RBZJEWEL
|
-0.056x |
|
SLP Resources Bhd
KLSE:7248
|
0.017x |
|
artnet AG Namens-Aktien o.N.
XETRA:ART
|
0.034x |
|
Circle8 Group, Inc.
NASDAQ:CIRC
|
N/A |
|
Transindia Real Estate Limited
NSE:TREL
|
0.012x |
|
CONCORD ENVIRO SYSTEMS L
NSE:CEWATER
|
-0.074x |
|
Pliant Therapeutics Inc
NASDAQ:PLRX
|
-0.116x |
|
HY Energy Group Co Ltd
SHG:600387
|
-0.044x |
Annual Cash Flow Conversion Efficiency for Akoya Biosciences Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Akoya Biosciences Inc from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Akoya Biosciences Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $7.59 Million | $-44.10 Million | -5.807x | -513.44% |
| 2023-12-31 | $53.77 Million | $-50.90 Million | -0.947x | -3.66% |
| 2022-12-31 | $58.58 Million | $-53.50 Million | -0.913x | -207.25% |
| 2021-12-31 | $121.35 Million | $-36.07 Million | -0.297x | +19.34% |
| 2020-12-31 | $18.57 Million | $-6.84 Million | -0.368x | -180.67% |
| 2019-12-31 | $-30.16 Million | $-13.78 Million | 0.457x | -- |
About Akoya Biosciences Inc
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions for transforming discovery, clinical research, and diagnostics in North America, the Asia-Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImag… Read more